[1] NATIONAL INSTITUTES OF HEALTH, CENTERS FOR DISEASE CONTROL AND PREVENTION, HIV MEDICINE ASSOCIATION, AND INFECTIOUS DISEASES SOCIETY OF AMERICA. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV[EB/OL].[2024-12-06]. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections [2] PHAIR J, MUÑOZ A, DETELS R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1[J]. N Engl J Med, 1990, 322(3): 161-165. [3] SALZER HJF, SCHÄFER G, HOENIGL M, et al. Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia[J]. Respiration, 2018, 96(1): 52-65. [4] IBRAHIM A, CHATTARAJ A, IQBAL Q, et al.Pneumocystis jiroveci Pneumonia: A Review of Management in Human Immunodeficiency Virus (HIV) and Non-HIV Immunocompromised Patients[J]. Avicenna J Med, 2023, 13(1): 23-34. [5] ELANGO K, MUDGAL M, MURTHI S, et al.Trends in the Epidemiology and Outcomes of Pneumocystis Pneumonia among Human Immunodeficiency Virus (HIV) Hospitalizations[J]. Int J Environ Res Public Health, 2022, 19(5): 2768. [6] 赵自利. 艾滋病机会性感染住院患者临床特征分析与生存预测研究[D]. 昆明:昆明医科大学, 2023. [7] 田波, 刘俊, 张丽华, 等. 昆明市2012~2020年HIV/AIDS住院患者的疾病谱[J]. 昆明医科大学学报, 2021, 42(8): 152-157. [8] ZENG YM, LI Y, LU YQ, et al.Initiating antiretroviral therapy within 2 weeks of anti-Pneumocystis treatment does not increase mortality or AIDS-defining events in patients with HIV-associated moderate to severe Pneumocystis pneumonia: results of a prospective observational multicenter study[J]. BMC Pulm Med, 2022, 22(1): 323. [9] HUANG Y, HE X, CHEN H, et al.No Statistically Apparent Difference in Antifungal Effectiveness Observed Among Trimethoprim/Sulfamethoxazole Plus Clindamycin or Caspofungin, and Trimethoprim/Sulfamethoxazole Monotherapy in HIV-Infected Patients with Moderate to Severe Pneumocystis Pneumonia: Results of an Observational Multicenter Cohort Study[J]. Infect Dis Ther, 2022, 11(1): 543-557. [10] 中华医学会感染病学分会艾滋病丙型肝炎学组.艾滋病合并肺孢子菌肺炎诊疗专家共识(2024年版)[J].中华临床感染病杂志,2024, 17(2): 81-92,98. [11] 中华医学会感染病学分会艾滋病丙型肝炎学组. 中国艾滋病诊疗指南(2024版)[J/CD]. 新发传染病电子杂志, 2024, 9(4): 68-94. [12] MCDONALD EG, AFSHAR A, ASSIRI B, et al.Pneumocystis jirovecii pneumonia in people living with HIV: a review[J]. Clin Microbiol Rev, 2024, 37(1): e0010122. [13] BROWN L, RAUTEMAA-RICHARDSON R, MENGOLI C, et al.Polymerase Chain Reaction on Respiratory Tract Specimens of Immunocompromised Patients to Diagnose Pneumocystis Pneumonia: A Systematic Review and Meta-analysis[J]. Clin Infect Dis, 2024, 79(1): 161-168. [14] BUTLER-LAPORTE G, SMYTH E, AMAR-ZIFKIN A, et al. Low-Dose TMP-SMX in the Treatment of Pneumocystis jirovecii Pneumonia: A Systematic Review and Meta-analysis[J]. Open Forum Infect Dis, 2020, 7(5): ofaa112. [15] ARMSTRONG-JAMES D, STEBBING J, JOHN L, et al.A trial of caspofungin salvage treatment in PCP pneumonia[J]. Thorax, 2011, 66(6): 537-538. [16] PROSTY C, KATERGI K, SORIN M, et al.Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials[J]. Clin Microbiol Infect, 2024, 30(7): 866-876. [17] SWINDELLS S, EVANS S, ZACKIN R, et al.Predictive value of HIV-1 viral load on risk for opportunistic infection[J]. J Acquir Immune Defic Syndr, 2002, 30(2): 154-158. [18] RAJASINGHAM R, GOVENDER NP, JORDAN A, et al.The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis[J]. Lancet Infect Dis, 2022, 22(12): 1748-1755. [19] 张莹, 张发珍, 鲁雁秋, 等. 中国艾滋病患者隐球菌脑膜炎患病率Meta分析[J].中国感染控制杂志, 2023, 22(7): 775-781. [20] 中华医学会感染病学分会艾滋病丙型肝炎学组. 艾滋病合并隐球菌病诊疗专家共识(2024年更新版)[J].中国艾滋病性病, 2024, 30(5): 447-458. [21] MCHALE TC, BOULWARE DR, KASIBANTE J, et al.Diagnosis and management of cryptococcal meningitis in HIV-infected adults[J]. Clin Microbiol Rev, 2023, 36(4): e0015622. [22] RHEIN J, BAHR NC, HEMMERT AC, et al.Diagnostic performance of a multiplex PCR assay for meningitis in an HIV-infected population in Uganda[J]. Diagn Microbiol Infect Dis, 2016, 84(3): 268-273. [23] TAY E, CHEN SC, GREEN W, et al.Development of a Real-Time PCR Assay to Identify and Distinguish between Cryptococcus neoformans and Cryptococcus gattii Species Complexes[J]. J Fungi (Basel), 2022, 8(5): 462. [24] DANTAS KC, DE FREITAS-XAVIER RS, SPINA LOMBARDI SCF, et al. Comparative analysis of diagnostic methods for the detection of Cryptococcus neoformans meningitis[J]. PLoS Negl Trop Dis, 2023, 17(3): e0011140. [25] SU Y, MIAO Q, LI N, et al.Diagnostic accuracy of metagenomic next-generation sequencing for cryptococcosis in immunocompetent and immunocompromised patients[J]. Front Cell Infect Microbiol, 2022, 12:997256. [26] LI Y, HUANG X, QIN Y, et al.What Is the Most Appropriate Induction Regimen for the of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis[J]. Front Pharmacol, 2020, 11:963. [27] JARVIS JN, LAWRENCE DS, MEYA DB, et al.Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis[J]. N Engl J Med, 2022, 386(12): 1109-1120. [28] SHAPIRO AE, TENFORDE MW, CHILLER TM, et al.An updated systematic review of HIV-associated cryptococcal meningitis treatment strategies[J]. HIV Med, 2023, 24(4): 507-512. [29] LOYSE A, BICANIC T, JARVIS JN.Combination antifungal therapy for cryptococcal meningitis[J]. N Engl J Med, 2013, 368(26): 2522. [30] ZHAO T, XU X, WU Y, et al.Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China[J]. BMC Infect Dis, 2022, 22(1): 677. [31] ZHAO H, LU Y, LI S, et al.Voriconazole plus flucytosine is not superior to amphotericin B deoxycholate plus flucytosine as an induction regimen for cryptococcal meningitis treatment[J]. Mycoses, 2024, 67(1): e13674. [32] WORLD HEALTH ORGANIZATION.Guidelines for Diagnosing, Preventing and Managing Cryptococcal Disease Among Adults, Adolescents and Children Living with HIV[M]. Geneva: World Health Organization, 2022. [33] ZHAO T, XU XL, LU YQ, et al.The Effect of Early vs. Deferred Antiretroviral Therapy Initiation in HIV-Infected Patients With Cryptococcal Meningitis: A Multicenter Prospective Randomized Controlled Analysis in China[J]. Front Med (Lausanne), 2021, 8:779181. [34] HU Y, ZHANG J, LI X, et al.Penicillium marneffei infection: an emerging disease in mainland China[J]. Mycopathologia, 2013, 175(1-2): 57-67. [35] 中华医学会感染病学分会艾滋病丙型肝炎学组. 艾滋病合并马尔尼菲篮状菌病诊疗专家共识(2024年更新版)[J]. 中国艾滋病性病, 2024, 30(6): 563-572. [36] 郑祎, 何云, 刘甲野, 等. 血清(1, 3)-β-D葡聚糖试验与血清半乳甘露聚糖试验对马尔尼菲篮状菌病的诊断价值[J]. 中国真菌学杂志, 2022, 17(5): 385-390. [37] XUE XC, ZOU J, FANG WJ, et al.Characteristics and prognosis of talaromyces marneffei infection in HIV-positive children in southern China[J]. Mycopathologia, 2022, 187(2/3): 169-180. [38] PRUKSAPHON K, INTARAMAT A, SIMSIRIWONG P, et al.An inexpensive point-of-care immunochromatographic test for Talaromyces marneffei infection based on the yeast phase specific monoclonal antibody 4D1 and Galanthus nivalis agglutinin[J]. PLoS Negl Trop Dis, 2021, 15(5): e0009058. [39] SHU FY, PRUKSAPHON K, NOSANCHUK JD, et al.Evaluation of the yeast phase-specific monoclonal antibody 4D1 and Galanthus nivalis agglutinin sandwich ELISA to detect Talaromyces marneffei antigen in human urine[J]. Front Cell Infect Microbiol, 2023, 13: 1163868. [40] PRUKSAPHON K, INTARAMAT A, RATANABANANGKOON K, et al.Diagnostic laboratory immunology for talaromycosis (penicilliosis): review from the bench-top techniques to the point-of-care testing[J]. Diagn Microbiol Infect Dis, 2020, 96(3): 114959. [41] THU NTM, CHAN JFW, LY VT, et al.Superiority of a novel Mp1p antigen detection enzyme immunoassay compared to standard BACTEC blood culture in the diagnosis of talaromycosis[J]. Clin Infect Dis, 2021, 73(2): e330-e336. [42] NING CY, LAI JZ, WEI WD, et al.Accuracy of rapid diagnosis of Talaromyces marneffei: a systematic review and meta-analysis[J]. PLoS One, 2018, 13(4): e0195569. [43] LIU LP, SUN BJ, YING WJ, et al.Rapid diagnosis of Talaromyces marneffei infection by metagenomic next-generation sequencing technology in a Chinese cohort of inborn errors of immunity[J]. Front Cell Infect Microbiol, 2022, 12: 987692. [44] ZHOU Y, LU T, LI Y, et al.Severe anemia, severe leukopenia, and severe thrombocytopenia of amphotericin B deoxycholate-based induction therapy in patients with HIV-associated talaromycosis: a subgroup analysis of a prospective multicenter cohort study[J]. BMC Infect Dis, 2023, 23(1): 707. [45] 覃江龙, 吴念宁, 梁纲. 艾滋病合并马尔尼菲青霉菌感染中枢神经系统1例[J].中国热带医学, 2018, 18(4): 410-412. [46] ZHOU Y, QIN Y, LU Y, et al.Efficacy and Safety of Voriconazole Versus Amphotericin B Deoxycholate Induction Treatment for HIV-Associated Talaromycosis: A Prospective Multicenter Cohort Study in China[J]. Infect Dis Ther, 2022, 11(4): 1575-1590. [47] QIN YY, ZHOU YH, LIU ST, et al.HIV-associated talaromycosis: does timing of antiretroviral therapy matter?[J]. J Infect, 2022, 84(3): 410-417. [48] 中华医学会感染病学分会艾滋病丙型肝炎学组, 陈耀凯, 李太生,等. 艾滋病合并弓形虫脑病诊疗专家共识(2024年更新版)[J]. 中国艾滋病性病, 2024, 30(6): 555-562. [49] WANG ZD, WANG SC, LIU HH, et al.Prevalence and Burden of, Toxoplasma Gondii, Infection in HIV-Infected People: a Systematic Review and Meta-Analysis[J]. Lancet HIV, 2017, 4(4):e177-e188. [50] DIAN S, GANIEM AR, EKAWARDHANI S.Cerebral toxoplasmosis in HIV-infected patients: a review[J]. Pathog Glob Health, 2023, 117(1): 14-23. [51] PROSTY C, HANULA R, LEVIN Y, et al.Revisiting the Evidence Base for Modern-Day Practice of the Treatment of Toxoplasmic Encephalitis: A Systematic Review and Meta-Analysis[J]. Clin Infect Dis, 2023, 76(3): e1302-e1319. [52] HERNANDEZ AV, THOTA P, PELLEGRINO D, et al.A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option?[J].HIV Med, 2017, 18(2): 115-124. [53] LI Y, JIANG HD, ZENG YM, et al.Optimal Timing of Antiretroviral Therapy Initiation in Acquired Immunodeficiency Syndrome-Associated Toxoplasmic Encephalitis:A Prospective Observational Multicenter Study in China[J]. Infectious Diseases & Immunity, 2024, 4(1):4-9. [54] 中华医学会感染病学分会艾滋病丙型肝炎学组. 艾滋病合并巨细胞病毒病诊疗专家共识(2024年版)[J]. 中华传染病杂志, 2024, 42:(3): 129-140. [55] ZHAO Q, LI NN, CHEN YX, et al.Clinical features of Cytomegalovirus retinitisin patients with acquired immunodeficiency syndrome and efficacy of the current therapy[J]. Front Cell Infect Microbiol, 2023, 13:1107237. [56] MOHAN S, DHANUREKHA L, JANANI MK, et al.Correlation of quantitative polymerase chain reaction with clinical characteristics of patients with viral retinitis[J]. Indian J Ophthalmol, 2022, 70(6): 2090-2093. [57] DU KF, HUANG XJ, CHEN C, et al.High Blood Cytomegalovirus Load Suggests Cytomegalovirus Retinitis in HIV/AIDS Patients: A Cross-Sectional Study[J]. Ocul Immunol Inflamm, 2022, 30(7-8): 1559-1563. [58] MARKAN A, GUPTA N, DOGRA M, et al.Oral valganciclovir in human immunodeficiency virus-positive patients suffering from cytomegalovirus retinitis at a tertiary care hospital in North India[J]. Indian J Ophthalmol, 2022, 70(7): 2472-2475. [59] LIANG X, AN H, HE H, et al.Comparison of two different intravitreal treatment regimens combined with systemic antiviral therapy for cytomegalovirus retinitis in patients with AIDS[J]. AIDS Res Ther, 2023, 20(1):46. [60] CHEN WB, LONG Z, HOU J, et al.Continuous High-Dose (6 mg) vs. Low-Dose (3 mg) Intravitreal Ganciclovir for Cytomegalovirus Retinitis After Haploidentical Hematopoietic Stem Cell Transplantation: A Randomized Controlled Study[J]. Front Med (Lausanne), 2021, 8:750760. [61] XIE LY, CHEN C, KONG WJ, et al.Effect of Anti-CMV Therapy at Different Stages on Retinal Detachment in Patients with AIDS and CMVR[J]. Adv Ther, 2021, 38(5):2294-2301. [62] XIE LY, LI XN, CHENh C, et al.Clinical efficacy of laser therapy in the prevention of retinal detachment in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis[J]. Quant Imaging Med Surg, 2021, 11(6):2634-2641. [63] SU YT, CHEN YJ, LIN CP, et al.Clinical Characteristics and Prognostic Factors Affecting Clinical Outcomes in Cytomegalovirus Retinitis with or without HIV Infection[J]. Retina, 2023, 43(1):57-63. |